PTC
DNTH icon

Private Trust Company’s Dianthus Therapeutics DNTH Stock Holding History

Private Trust Company’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.16K Buy
94
+24
+34% +$2.1K ﹤0.01% 2113
2026
Q1 		$5.87K Buy
+70
New +$4.05K ﹤0.01% 2159

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Private Trust Company's DNTH Position: Q2 2026 in Review

Private Trust Company increased its Dianthus Therapeutics (DNTH) stake by 34% in Q2 2026, buying an estimated $2.1K and bringing the position to 94 shares worth $9.16K. The position accounts for ﹤0.01% of the portfolio, ranked #2113.

Private Trust Company first reported a position in DNTH in Q1 2026 and has held it in 2 quarters since. 268 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Private Trust Company held 94 shares of Dianthus Therapeutics worth $9.16K as of Q2 2026.
  • Private Trust Company bought 24 Dianthus Therapeutics shares in Q2 2026, an estimated $2.1K.
  • Dianthus Therapeutics made up ﹤0.01% of Private Trust Company's portfolio in Q2 2026, its #2113 holding.
  • Private Trust Company first reported a position in Dianthus Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 268 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Private Trust Company's 13F filing for Q2 2026, filed 28 Jul 2026.